{"public_id":"co_92bd9acc4103889517cfc2297306f2eb","status":"active","merged_into_public_id":null,"resolved_public_id":"co_92bd9acc4103889517cfc2297306f2eb","name":"poor adherence","description":"Low compliance with the prescribed imatinib regimen, including adherence at or below the thresholds analyzed.","aliases":[],"types":["measure"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"concept","status":"active","confidence":null,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","concept.status"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"papers":[{"corpus_id":8302472,"title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.","citation_count":909,"url":"https://sah.borca.ai/papers/8302472"}],"claims":[{"public_id":"cl_9d862a0ecc7466678270e512f62bb1e0","text":"Poor adherence is the predominant reason for failure to obtain adequate molecular responses in chronic myeloid leukemia patients treated with imatinib over several years.","corpus_id":8302472,"url":"https://sah.borca.ai/claims/cl_9d862a0ecc7466678270e512f62bb1e0"}],"related_concepts":[],"resolved_url":"https://sah.borca.ai/concepts/co_92bd9acc4103889517cfc2297306f2eb","url":"https://sah.borca.ai/concepts/co_92bd9acc4103889517cfc2297306f2eb"}